The House Energy and Commerce (E&C) Committee released a report today entitled “Review of the 340B Drug Pricing Program.”  The report covers a wide range of topics under the 340B program and makes several recommendations, including a “clarification” of the intent of the program, increased regulatory authority for HRSA, increased oversight of both covered entities and manufacturers, increased transparency requirements for covered entities and manufacturers, and a review of the eligibility requirements for hospitals.  We will be analyzing the report in greater detail and providing a  more in depth summary as soon as possible.